The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics

Journal of the American Academy of Dermatology

Volumn 66, Issue 5, 2012, Pages

  Iwasaki, Julie K ^a   Srivastava, Divya ^b   Moy, Ronald L ^c,d   Lin, Henry J ^c,e   Kouba, David J ^a,f  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f Toledo Clinic Dermasurgery and Laser Center   (United States)

Author keywords

basal cell; carcinoma; sonic hedgehog

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; COLECALCIFEROL; CYCLOPAMINE; FORKHEAD TRANSCRIPTION FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYC PROTEIN; N (3 METHOXYBENZYL) 3,3 DIMETHYL N [1 (3,4 METHYLENEDIOXYBENZYL) 2 (1 PIPERAZINYLCARBONYL) 4 PYRROLIDINYL]BUTYRAMIDE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BCL 2; RAPAMYCIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR RUNX; UNCLASSIFIED DRUG; VISMODEGIB;

BASAL CELL CARCINOMA; CARCINOGENESIS; CELL PROLIFERATION; HUMAN; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, BASAL CELL; COHORT STUDIES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEDGEHOG PROTEINS; HUMANS; MALE; MICE; MOLECULAR BIOLOGY; MUTATION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84859847132     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.06.054     Document Type: Review

References (50)

1. Daya-Grosjean L, Couve-Privat S. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 2005;225:181-92. (Pubitemid 40835865)
2. Oberyszyn TM. Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D. Cancer Lett 2008;261:127-36.
3. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006;19(Suppl. 2):S127-47. (Pubitemid 43172313)
4. Szeimies RM, Karrer S. Towards a more specific therapy: targeting nonmelanoma skin cancer cells. Br J Dermatol 2006;154(Suppl. 1):16-21.
5. Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci U S A 2003;100:4616-21. (Pubitemid 36457779)
6. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002;62:4773-80.
7. Bale AE. Hedgehog signaling and human disease. Annu Rev Genomics Hum Genet 2002;3:47-65. (Pubitemid 35217430)
8. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signalling in skin development and cancer. Exp Dermatol 2006;15:667-77. (Pubitemid 44145237)
9. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71. (Pubitemid 26200029)
10. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841-51. (Pubitemid 26192135)
11. Bonifas JM, Pennypacker S, Chuang PT, McMahon AP, Williams M, Rosenthal A, et al. Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol 2001;116:739-42. (Pubitemid 32467653)
12. Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 2006;7:841-50. (Pubitemid 44607100)
13. Eichberger T, Regl G, Ikram MS, Neill GW, Philpott MP, Aberger F, et al. FOXE1, a new transcriptional target of GLI2 is expressed in human epidermis and basal cell carcinoma. J Invest Dermatol 2004;122:1180-7. (Pubitemid 38651093)
14. Agren M, Kogerman P, Kleman MI, Wessling M, Toftgard R. Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene 2004;330:101-14. (Pubitemid 38490423)
15. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-803. (Pubitemid 28217449)
16. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001;15:3059-87. (Pubitemid 33115673)
17. Lacour JP. Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol 2002;146(Suppl. 61):17-9. (Pubitemid 34437805)
18. Roy S, Ingham PW. Hedgehogs tryst with the cell cycle. J Cell Sci 2002;115:4393-7. (Pubitemid 36004401)
19. Barnes EA, Heidtman KJ, Donoghue DJ. Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC. Oncogene 2005;24:902-15. (Pubitemid 40216098)
20. Bigelow RL, Chari NS, Unden AB, Spurgers KB, Lee S, Roop DR, et al. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 2004;279:1197-205. (Pubitemid 38082643)
21. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2. (Pubitemid 28079221)
22. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC, et al. RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 2006;25:7646-9. (Pubitemid 44924477)
23. Saldanha G, Ghura V, Potter L, Fletcher A. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 2004;151:157-64. (Pubitemid 39061293)
24. Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular biological update. Br J Dermatol 2003;148:195-202. (Pubitemid 36278957)
25. Howell BG, Solish N, Lu C, Watanabe H, Mamelak AJ, Freed I, et al. Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. J Dermatol Sci 2005;39:39-51. (Pubitemid 40835832)
26. Freier K, Flechtenmacher C, Devens F, Hartschuh W, Hofele C, Lichter P, et al. Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep 2006;15:1141-5.
27. Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alboran IM, Olson JM, et al. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res 2006;66:8655-61. (Pubitemid 44449181)
28. Ozakyol A, Ozdemir M, Artan S. Fish detected p53 deletion and N-MYC amplification in colorectal cancer. Hepatogastroenterology 2006;53:192-5.
29. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-87. (Pubitemid 40637829)
30. Wicking C, McGlinn E. The role of hedgehog signalling in tumorigenesis. Cancer Lett 2001;173:1-7. (Pubitemid 32907502)
31. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005-9.
32. Athar M, Li C, Tang X, Chi S, Zhang X, Kim AL, et al. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res 2004;64:7545-52. (Pubitemid 39372099)
33. Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 2004;14:96-102. (Pubitemid 38510025)
34. Von Hoff D, LoRusso P, Rudin C, Reddy J, Yauch R, Tibes R, et al. Inhibition of the Hedgehog Pathway in Advanced Basal Cell Carcinoma. N Engl J Med 2009;361:1164-72.
35. Dlugosz AA, Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med 2009;361:1202-5.
36. Vogt A, Chuang PT, Hebert J, Hwang J, Lu Y, Kopelovich L, et al. Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J Exp Med 2004;199:753-61. (Pubitemid 38375195)
37. Jenkins D. Hedgehog signalling: Emerging evidence for noncanonical pathways. Cell Signal 2009;21:1023-34.
38. Luoro I, McKie-Bell P, Gosnell H, Brindley B, Bucy R, Ruppert M. The Zinc Finger Protein GLI Induces Cellular Sensitivity to the mTOR Inhibitor Rapamycin. Cell Growth & Differentiation 1999;10:503-16. (Pubitemid 29344692)
39. Tang JY, So PL, Epstein EH Jr. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol 2007;224:257-64. (Pubitemid 47575674)
40. Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol 2006;4:e232.
41. Link between vitamin D and basal cell carcinoma probed: Study sheds light on development of most common form of skin cancer. Available at: http://www.sciencedaily.com/releases/2010/03/100304131609.htm. Accessed August 18, 2010.
42. Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 1996;383:407-13. (Pubitemid 26330823)
43. Corcoran RB, Scott MP. Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc Natl Acad Sci U S A 2006;103:8408-13. (Pubitemid 43838468)
44. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004;350:1579-82. (Pubitemid 38477791)
45. Black HS, Thornby JI, Wolf JE Jr, Goldberg LH, Herd JA, Rosen T, et al. Evidence that a low-fat diet reduces the occurrence of non-melanoma skin cancer. Int J Cancer 1995;62:165-9.
46. Taipale J, Cooper MK, Maiti T, Beachy PA. Patched acts catalytically to suppress the activity of Smoothened. Nature 2002;418:892-7. (Pubitemid 34966310)
47. Hoi CS, Lee SE, Lu SY, McDermitt DJ, Osorio KM, Piskun CM, et al. Runx1 directly promotes proliferation of hair follicle stem cells and epithelial tumor formation in mouse skin. Mol Cell Biol 2002;30:2518-36.
48. Li X, Hoeppner LH, Jensen ED, Gopalakrishnan R, Westendorf JJ. Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors. J Cell Biochem 2009;108:378-87.
49. Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther 2010;9:1396-407.
50. Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 2009;4:e5592.